Trial Profile
An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Oesophagitis Who Completed Study Res-5-0002 [EXTENSION OF 700027517]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Reslizumab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Adverse reactions; Registrational
- Sponsors Ception Therapeutics
- 12 Apr 2014 New trial record
- 09 Apr 2012
- 02 Feb 2010